← Leaderboards
Joshua R Veatch
Fred Hutchinson Cancer Research Center
$2,358,295
Attributed
$2,358,295
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $888K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,358,295 · 2
By mechanism
R37$1,387,760 · 1
K08$970,535 · 1
Top collaborators
No co-investigators on record.
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Jennifer M Lund$18,457,976
- Florian Hladik$13,775,431
- Amanda G Paulovich$38,180,578
- Ann C Duerr$21,182,270
- Manish Sagar$13,597,051
Others in their field
Other Emerging Leaders on “Mouse Model”
- James Dale Berry · Brigham And Women'S Hospital$25,017,559
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$13,186,126
- Nuno Macarico Da Costa · Allen Institute$11,726,937
- Forrest Christie Collman · Allen Institute$11,726,937
- Jacqueline K White · Jackson Laboratory$11,670,339
- Thomas Dick · Rbhs-New Jersey Medical School$11,611,284
Research focus
Mouse ModelSingle-Cell Rna SequencingImmunotherapyMelanomaResponseSignal TransductionEngineered T CellsImmune ResponseMalignant NeoplasmsMediatingAdoptive TransferNeoplastic CellAntigen-Presenting CellsCorrelative StudyClinical TrialsCancer CellImmuneImmune ActivationCancer PatientCancer TherapyCd4 Positive T LymphocytesCellsCd8-Positive T-LymphocytesSite
Grant awards (7)
Targeting the tumor microenvironment with engineered CD4+ T cells$693,880
R37 · FY2025 · CA · contact PI
Targeting the tumor microenvironment with engineered CD4+ T cells$693,880
R37 · FY2024 · CA · contact PI
Therapeutic applications of CD4+ T cells specific for oncogenic driver mutations$194,107
K08 · FY2024 · CA · contact PI
Therapeutic applications of CD4+ T cells specific for oncogenic driver mutations$194,107
K08 · FY2023 · CA · contact PI
Therapeutic applications of CD4+ T cells specific for oncogenic driver mutations$194,107
K08 · FY2022 · CA · contact PI
Therapeutic applications of CD4+ T cells specific for oncogenic driver mutations$194,107
K08 · FY2021 · CA · contact PI
Therapeutic applications of CD4+ T cells specific for oncogenic driver mutations$194,107
K08 · FY2020 · CA · contact PI